"The current drug approved by the U.S. Food and Drug Administration to treat hepatocellular carcinoma only increases the average survival of patients by about three months," said Kevin Staveley-O'Carroll, chair of the MU School of Medicine's Hugh E. Stephenson Jr., Department of Surgery and director of Ellis Fischel Cancer Center. "While any extension of life is valuable, our research team is developing a new therapeutic strategy that might extend and improve the quality of life for these patients."

During the study, one group of mice was treated with the chemotherapy agent sunitinib and another group was treated with an immunotherapy antibody known as anti-PD-1. Over a period of four weeks, tumors in mice treated with sunitinib grew 25 times larger.

Tumors in mice treated with immunotherapy grew at a slower rate and were 15 times larger. However, a third group of mice treated with a combination of chemotherapy and immunotherapy experienced even slower tumor growth at a size that was only 11 times larger.

"Our results show that a combined chemo-immunotherapeutic approach can slow tumor growth in mice more effectively than either individual treatment," said Guangfu Li, assistant professor in the MU Department of Surgery. "This innovative combination promotes an anti-tumor immune response and better suppresses growth of the cancer. Our findings support the need for a clinical trial to test whether this could become a cost-effective treatment that could help improve the lives of patients with liver cancer."

Source: Eurekalert